Reply to Letter to Editor from Juan-Enrique Schwarze and colleagues – Critical appraisal on “Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France”

0 avis

Reply to Letter to Editor from Juan-Enrique Schwarze and colleagues – Critical appraisal on “Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France”

Archive ouverte

Edité par CCSD ; Elsevier -

International audience. No abstract available

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France

Archive ouverte | Lehmann, Matthieu | CCSD

International audience. Objective: The study assessed cost-effectiveness of follitropin alfa biosimilar versus the originator in terms of cost per cumulative live-birth (CLB) for the French healthcare system based o...

A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose

Archive ouverte | Barrière, Paul | CCSD

International audience. Background: Since the first launch of a biosimilar recombinant follicle stimulating hormone (rFSH), Bemfola®, in Europe in 2014, it has been possible to study in routine clinical care through...

Effects of eight neuropsychiatric copy number variants on human brain structure

Archive ouverte | Modenato, Claudia | CCSD

International audience. Many copy number variants (CNVs) confer risk for the same range of neurodevelopmental symptoms and psychiatric conditions including autism and schizophrenia. Yet, to date neuroimaging studies...

Chargement des enrichissements...